And while the many of the problems are well known, such as bad incentives for doctors, patients trained to equate over-testing and over-treatment with high quality care, high administration costs, and unrestricted drug pricing (despite lavish public funding of drug research), Obamacare has sided with industry incumbents, namely Big Pharma and health care insurers, at the expense of everyone else.